FDA has denied FDA approval of Ocugen's emergency use of COVAXIN to prevent COVID-19 in persons aged 2 to 18 years. The company will continue to work with the FDA to evaluate the regulatory mechanism for pediatric use of the drug.
FDA has denied FDA approval of Ocugen's emergency use of COVAXIN to prevent COVID-19 in persons aged 2 to 18 years. The company will continue to work with the FDA to evaluate the regulatory mechanism for pediatric use of the drug. 
ocugen.gcs-web.com
English (US) 